Regression of endometriosis following shorter treatment with, or lower dose of danazol: Comparison of pre‐ and post‐treatment laparoscopic findings in the Scandinavian multi‐center study

A Döberl, Anton Döberl, Agneta Bergqvist, A Bergqvist, Sten Jeppsson, S Jeppsson, Aarne I. Koskimies, A I Koskimies, Lars Rönnberg, L Rönnberg, E Segerbrand, J Starup, Jørgen Starup
Acta obstetricia et gynecologica Scandinavica. Supplement · 1984 · vol. 63(S123) , pp. 51–58 · doi:10.3109/00016348409156982 · PMID:6238497 · W2127999736
article OA: closed CC0 ⤵ 16 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study compared danazol treatment regimens for endometriosis, finding that 600 mg daily for 6 months resulted in greater regression than 4 months of 600 mg daily, though dose reduction after 2 months increased irregular bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Abstract. One hundred and sixteen patients with laparosco‐pically confirmed primary or recurrent endometriosis were treated with danazol, either 600 mg daily for 4 months (group A, n = 76) or 600 mg daily for the first 2 months, followed by 400 mg daily for an additional 4 months (group B, n = 40). The only surgery performed before treatment was biopsies, resection of endometriomas 23 cm and/or adhe‐siolysis. The extent of endometriosis before and after treatment was established laparoscopically and recorded by means of a modified AFS record as mean additive diameter of implants (mean ADI) in millimeters. This provided a uniform and reproducible quantitative registration for each type and location of endometriotic implant. Both treatment schemes resulted in a highly significant (p<0.001) reduction of endometriosis, by 79 and 89% in groups A and B, respectively. However, the reduction in mean ADI was significantly greater (p< 0.025) in group B which had been treated for a longer period. Morevoer, the proportion of patients with extensive pre‐treatment lesions (mean ADI 240 mm) was significantly greater in this group. Active residual endometriosis was found in 21 and 17.5% in groups A and B, respectively. These patients had significantly more extensive endometriosis before treatment. The regression of endometriotic implants was independent of type and/or location, i.e. superficial or scarred; peritoneal, ovarian, or tuba]. There was no apparent correlation between the quantitative reduction of endometriosis and amenorrhea versus occasional spotting and/or irregular menstruations. Despite the marked reduction of endometriotic tissue following both treatment schemes, only 4 months of treatment with 600 mg daily appears to be too short a period to ensure elimination of endometriosis, leaving a number of small residues at the end of treatment. Six month's treatment according to schedule B produced a significantly greater reduction in endometriotic tissue, but lowering of the dose to 400 mg daily after 2 months was associated with a significant increase of irregular vaginal bleeding. Although the choice of danazol dose and duration of treatment in endometriosis depends on the objective and approach in the individual case, the authors do not feel confident in recommending less than 600 mg daily for 6 months, if a high probability of complete resolution of all endometriotic implants, other than endometriomas, is desired.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Danazol Endometriosis Pregnadienes Adult Amenorrhea Amenorrhea Danazol Endometriosis Endometriosis Endometriosis Female Humans Laparoscopy Pregnadienes Scandinavian and Nordic Countries

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Cited by (16)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:55.985569+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK